How to get Strattera fast in Texas

If you’re navigating ADHD treatment options, you’ve probably wondered: Can I actually get prescribed ADHD medication through a video call? The short answer is yes—especially for non-stimulant medications like Strattera (atomoxetine). But as with most things in healthcare, the complete answer involves understanding federal rules, state-specific laws, and what your provider needs to safely prescribe ADHD treatment remotely.

In this comprehensive guide, we’ll walk you through everything you need to know about getting ADHD non-stimulant medication via telehealth in 2025, including current regulations, state-by-state differences, what to expect from your virtual appointment, and how to navigate this evolving landscape of care.

Understanding ADHD Non-Stimulant Medications

Before diving into telehealth regulations, let’s clarify what we mean by ‘non-stimulant’ ADHD medications.

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications offer an alternative treatment pathway for ADHD that doesn’t involve amphetamine or methylphenidate-based drugs. The most commonly prescribed non-stimulant is Strattera (atomoxetine), but others include:

• Strattera (atomoxetine) – A selective norepinephrine reuptake inhibitor
• Intuniv (guanfacine) – An alpha-2 adrenergic agonist
• Kapvay (clonidine) – Another alpha-2 adrenergic agonist
• Qelbree (viloxazine) – A newer norepinephrine reuptake inhibitor

Why This Matters for Telehealth

Here’s the critical distinction: Non-stimulant ADHD medications are not controlled substances. Strattera, for example, is not classified by the DEA as a Schedule II-V controlled drug. This means it doesn’t fall under the strict federal prescribing rules that govern stimulant medications like Adderall or Ritalin.

Practically speaking, this makes non-stimulants much easier to prescribe via telehealth. There’s no federal requirement for an initial in-person examination before prescribing Strattera, and you won’t face the monthly prescription limits that apply to stimulants.

Who Benefits Most from Non-Stimulants?

Non-stimulant medications may be the right choice if you:

• Have a history of substance use concerns
• Experience problematic side effects from stimulants (like insomnia, appetite loss, or anxiety)
• Have certain medical conditions (heart issues, high blood pressure, glaucoma)
• Prefer a medication without abuse potential
• Need consistent 24-hour symptom coverage
• Want to avoid the stigma some associate with controlled substances

That said, non-stimulants typically take 4-6 weeks to reach full effectiveness, whereas stimulants work within hours. Your telehealth provider will help you weigh these considerations.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Current Federal Landscape: What’s Allowed in 2025

DEA Telehealth Flexibilities: Extended Through December 31, 2025

The COVID-19 pandemic fundamentally changed how controlled substances can be prescribed via telehealth. In November 2024, the DEA finalized its ‘Third Temporary Extension,’ allowing healthcare providers to continue prescribing Schedule II-V controlled substances through telehealth without a prior in-person examination through December 31, 2025.

Important clarification: While this primarily impacts stimulant ADHD medications (which are Schedule II controlled substances), it’s essential context for understanding the broader telehealth prescribing environment. A fourth extension for 2026 is currently under review, but nothing is guaranteed.

Non-Stimulants: Never Subject to Federal Restrictions

Here’s the key takeaway: Non-stimulant ADHD medications like Strattera have never been restricted by the Ryan Haight Act or DEA telehealth rules. Since they’re not controlled substances, providers have always been able to prescribe them via telehealth, subject only to standard medical practice guidelines and state licensing requirements.

This means even if federal controlled substance rules change in 2026, your access to non-stimulant ADHD medications through telehealth platforms like Klarity Health should remain unaffected.

What the Ryan Haight Act Actually Requires

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 typically requires an in-person medical evaluation before prescribing controlled substances via telemedicine. However:

1. This law applies only to controlled substances (Schedules II-V)
2. COVID-era waivers have suspended this requirement through 2025
3. Non-controlled medications like Strattera were never covered by this law

If you’re pursuing non-stimulant treatment, the Ryan Haight Act simply doesn’t apply to your situation.

State-by-State Telehealth Rules: Where Can You Get Treatment?

While federal law sets the baseline, states have significant authority over medical practice, including telehealth. Let’s examine how key states approach ADHD medication prescribing via telehealth.

States with Broad Telehealth Access

CaliforniaCalifornia embraces telehealth for ADHD treatment without requiring in-person visits for non-controlled medications. The state considers a proper telehealth video examination to satisfy the ‘good faith exam’ standard required before prescribing. Nurse practitioners in California have independent practice authority (following AB 890), meaning experienced NPs can diagnose and treat ADHD without physician oversight.

TexasTexas is particularly telehealth-friendly for behavioral health conditions like ADHD. The state explicitly permits telemedicine for mental health care, and there’s no mandate for in-person visits when prescribing non-stimulant medications. However, note that Texas does restrict NP/PA prescribing of Schedule II stimulants to hospital or hospice settings—but this doesn’t affect non-stimulant prescribing or physician prescribing rights.

IllinoisIllinois has embraced permanent telehealth expansion and allows full-scope practice for experienced nurse practitioners. Providers can establish a patient relationship and prescribe ADHD medications via telehealth without in-person requirements, making it one of the more accessible states for remote ADHD care.

PennsylvaniaPennsylvania’s Telemedicine Act (enacted in 2020) made telehealth practice permanent. The state doesn’t mandate in-person exams for ADHD treatment via telehealth, though providers must maintain appropriate standards of care and follow PDMP requirements for controlled substances.

States with Additional Requirements

New YorkNew York implemented stricter rules in May 2025, requiring an initial in-person evaluation before prescribing any controlled substance via telemedicine. However, this rule doesn’t affect non-stimulant medications. If you’re pursuing Strattera or other non-controlled ADHD medications in New York, you can receive a complete evaluation and prescription via telehealth without an in-person visit.

New York also grants nurse practitioners full independent practice authority after completing 3,600 supervised hours, expanding access to qualified ADHD care providers.

FloridaFlorida has specific rules about Schedule II controlled substance prescribing via telehealth, generally prohibiting it unless treating a psychiatric disorder (ADHD qualifies), or the patient is hospitalized, in hospice, or in a nursing facility. For non-stimulant medications, Florida imposes no special restrictions beyond standard telehealth requirements.

Florida does require checking the Prescription Drug Monitoring Program (PDMP) before every controlled substance prescription, though this doesn’t apply to Strattera since it’s not controlled.

New HampshireNew Hampshire recently modernized its approach. In August 2025, the state removed its prior in-person requirement through SB 252, now only requiring an annual follow-up evaluation (which can be conducted via telehealth) for ongoing controlled medication prescribing. For non-controlled medications, there are no additional requirements beyond standard medical practice.

NH also allows nurse practitioners full independent practice, including controlled substance prescribing authority.

States with Stricter Oversight

AlabamaAlabama maintains one of the most restrictive telehealth environments. The state requires an in-person visit within 12 months for patients receiving ongoing telehealth treatment for most conditions. However, there’s an important exception: mental health services are exempt from this rule.

Since ADHD is classified as a psychiatric/mental health condition, the 12-month in-person requirement may not apply to your ADHD treatment. That said, Alabama also has a unique requirement that a licensed medical professional must be physically present with the patient during initial controlled substance telehealth visits—creating what some call the ‘Alabama Loophole.’ This doesn’t affect Strattera prescribing but shows the state’s cautious approach.

GeorgiaGeorgia doesn’t require in-person visits for telehealth prescribing of non-controlled medications, but the state notably restricts nurse practitioner and physician assistant authority. Georgia NPs cannot prescribe Schedule II controlled substances, even with physician collaboration. For non-stimulant medications, however, NPs and PAs can prescribe under collaborative agreements.

What to Expect from Your Telehealth ADHD Evaluation

Getting ADHD medication via telehealth isn’t as simple as filling out a questionnaire. Legitimate providers follow rigorous diagnostic protocols to ensure patient safety and appropriate treatment.

The Comprehensive Intake Process

When you schedule an ADHD evaluation through a platform like Klarity Health, expect:

Detailed Medical HistoryYour provider will ask about:

• Current symptoms and how they impact daily life
• Childhood symptoms (ADHD symptoms must begin before age 12)
• Family history of ADHD or other mental health conditions
• Previous ADHD diagnoses or treatments
• Other medical conditions and current medications
• Substance use history
• Mental health history (depression, anxiety, bipolar disorder, etc.)

Symptom AssessmentProviders use standardized screening tools based on DSM-5 criteria, which require symptoms in at least two settings (home, work, school, social situations). You might complete:

• ADHD rating scales
• Executive function questionnaires
• Impact assessments measuring how symptoms affect relationships, work, or school

Collateral InformationMany providers request input from family members, partners, or close friends who can verify symptoms occur across multiple settings. For younger patients, parent/teacher input is essential. Some adults find it helpful to provide old report cards showing childhood attention challenges.

Safety ScreeningYour provider will assess:

• Cardiovascular health (non-stimulants can affect blood pressure and heart rate)
• Mental health stability (to rule out conditions that might contraindicate treatment)
• Substance use risk factors
• Medication contraindications (like MAOIs or certain heart conditions)

The Video Consultation

Your telehealth appointment typically lasts 30-60 minutes for an initial evaluation. During the video call, your provider will:

• Observe your presentation and behavior
• Ask clarifying questions about your symptoms
• Explain ADHD and how medications work
• Discuss treatment options (medication, therapy, lifestyle modifications)
• Review risks, benefits, and side effects
• Answer your questions
• Develop a treatment plan tailored to your needs

For non-stimulant medications like Strattera, your provider will explain:

• It takes 4-6 weeks for full therapeutic effect
• Dosing usually starts low and gradually increases
• Common side effects (upset stomach, decreased appetite, fatigue, mood changes)
• Important warnings (increased risk of suicidal thoughts in youth, rare liver problems)
• The need for follow-up appointments to monitor response

Follow-Up Care

Telehealth doesn’t end with the prescription. Expect:

• Short-term follow-up (2-4 weeks) to assess initial response and side effects
• Ongoing management (typically monthly initially, then every 3 months once stable)
• Dose adjustments based on symptom improvement and tolerability
• Integration with therapy or coaching for comprehensive ADHD management

Quality telehealth providers like Klarity Health coordinate care with your primary care provider when appropriate and maintain detailed records accessible across your care team.

Who Can Prescribe ADHD Medications via Telehealth?

Understanding which types of providers can treat your ADHD helps you navigate telehealth platforms effectively.

Physicians (MD/DO)

Licensed physicians can prescribe all ADHD medications—stimulants and non-stimulants—via telehealth in every state, as long as they:

• Hold an active medical license in your state
• Have DEA registration (for controlled substances)
• Follow applicable federal and state regulations
• Maintain appropriate standards of care

Nurse Practitioners (NP)

Nurse practitioner prescribing authority varies significantly by state:

Full Practice Authority StatesOver 25 states now grant experienced NPs independent practice rights, including:

• California (after meeting AB 890 requirements)
• New York (after 3,600 supervised hours)
• Illinois
• New Hampshire
• Arizona
• Colorado
• And many others

In these states, qualified NPs can diagnose ADHD, prescribe both stimulant and non-stimulant medications, and provide complete care without physician oversight.

Reduced Practice/Collaborative Agreement StatesMany states require NPs to maintain collaborative relationships with physicians but still grant broad prescribing authority:

• Florida (collaborative agreement required; some limitations on Schedule II prescribing)
• Pennsylvania (collaborative agreement with some autonomy)
• Ohio
• Michigan

Restricted Practice StatesA handful of states significantly limit NP authority:

• Texas (NPs cannot prescribe Schedule II stimulants in outpatient settings)
• Georgia (NPs cannot prescribe Schedule II drugs at all)
• Alabama (requires special permits for controlled substances)

For non-stimulant medications, NPs in virtually all states can prescribe with at least a collaborative agreement, making platforms that employ both physicians and NPs valuable for access.

Physician Assistants (PA)

Physician assistants typically practice under physician supervision, with prescribing authority that varies by state and the supervising physician’s delegation. Most states allow PAs to prescribe non-controlled ADHD medications like Strattera under appropriate supervision.

For Schedule II stimulants, PA authority is more limited and state-specific. Texas, for example, restricts PA Schedule II prescribing to hospital and hospice settings.

Choosing Your Provider

When using telehealth platforms like Klarity Health, you’ll be matched with an appropriately licensed provider based on:

• Your state’s regulations
• Provider availability
• The type of medication you may need
• Your specific clinical situation

Klarity ensures all providers hold active licenses in your state and appropriate DEA registrations when needed, taking the guesswork out of compliance.

Insurance, Costs, and Access Considerations

Insurance Coverage for Telehealth ADHD Treatment

Most insurance plans now cover telehealth mental health services at parity with in-person care, thanks to regulations implemented during and after the COVID-19 pandemic. This typically includes:

• Initial diagnostic evaluations
• Medication management appointments
• Therapy or counseling sessions
• Follow-up visits

Check your specific plan for:

• Whether your telehealth provider is in-network
• Copay amounts (often the same as in-person visits)
• Any prior authorization requirements
• Prescription coverage tiers

Klarity Health accepts various insurance plans and offers transparent pricing, helping you understand costs before your appointment.

Cash-Pay Options

If you don’t have insurance or prefer not to use it, many telehealth platforms offer cash-pay services with predictable pricing:

• Initial evaluation: Typically $199-299
• Follow-up appointments: Usually $99-149
• Medication costs: Varies by pharmacy and medication (Strattera generic is typically $30-100/month)

Cash-pay can be advantageous if you:

• Have high deductibles that haven’t been met
• Prefer privacy (insurance claims create records)
• Want faster appointment access
• Are between insurance coverage

Medication Costs and Assistance

Generic atomoxetine (Strattera’s generic form) costs significantly less than brand-name, typically $30-100 monthly at major pharmacies. To reduce costs:

• Use GoodRx or similar discount programs
• Check if your pharmacy offers generic discount programs
• Ask about 90-day supplies (often cheaper per month)
• Inquire about manufacturer patient assistance programs if prescribed brand-name

Unlike stimulants, non-stimulants can be prescribed in 90-day supplies, reducing pharmacy trips and potentially lowering costs through bulk pricing.

Addressing Common Concerns and Misconceptions

‘Online ADHD Prescriptions Are Too Easy to Get’

This misconception stems from 2022-2023 media coverage of companies like Cerebral and Done facing regulatory scrutiny. In reality, legitimate telehealth ADHD care requires thorough evaluation.

Reputable providers:

• Conduct comprehensive diagnostic assessments
• Use validated screening tools
• Require video consultations (not just questionnaires)
• Implement safety protocols and monitoring
• Follow up regularly to assess treatment response
• Coordinate with other providers when appropriate

Red flags to avoid:

• Services guaranteeing prescriptions
• Providers who don’t conduct video visits
• Platforms that skip thorough history-taking
• Services that don’t require follow-up appointments

Klarity Health follows rigorous clinical protocols aligned with best practices in psychiatry and primary care, ensuring you receive safe, appropriate treatment.

‘Telehealth Can’t Provide Quality ADHD Care’

Research increasingly supports telehealth for ADHD treatment. Studies show:

• Diagnostic accuracy via telehealth matches in-person evaluation when proper protocols are followed
• Treatment outcomes are comparable to traditional care
• Patient satisfaction is often higher due to convenience
• Adherence may improve due to reduced barriers to follow-up appointments

Telehealth is particularly well-suited for ADHD because:

• The diagnosis relies heavily on reported symptoms and history (not physical examination)
• Medication management primarily involves monitoring symptom response
• Regular check-ins are crucial for optimization—easier to maintain via telehealth
• Many ADHD patients struggle with appointment attendance; telehealth removes transportation and scheduling barriers

‘Non-Stimulants Don’t Work as Well’

While stimulants are considered first-line treatment for ADHD, non-stimulants work very effectively for many patients. Research shows:

• Strattera reduces ADHD symptoms in 60-70% of patients who complete an adequate trial
• Effect sizes are clinically meaningful, though often smaller than stimulants
• Benefits are sustained over time without tolerance development
• Different patients respond differently—some do better on non-stimulants

Non-stimulants offer unique advantages:

• No abuse potential or risk of diversion
• Smoother, all-day symptom coverage (no ‘wearing off’)
• May help with co-occurring anxiety
• Can be prescribed in longer supplies
• No controlled substance regulations

Your provider will help you weigh individual factors to determine the best starting medication for your situation.

‘My Pharmacy Won’t Fill Telehealth Prescriptions’

Most pharmacies readily fill legitimate telehealth prescriptions. Electronic prescriptions (e-prescribing) are standard practice and don’t indicate whether your visit was virtual or in-person.

Some pharmacies did temporarily scrutinize certain online stimulant prescriptions during the 2023 regulatory uncertainty, but this primarily affected controlled substances from companies under investigation.

To ensure smooth pharmacy experiences:

• Use a consistent, reputable pharmacy
• Choose well-established telehealth providers
• Ensure your provider uses e-prescribing
• Communicate with your pharmacist if questions arise

For non-stimulants like Strattera, you’re very unlikely to encounter any issues since they’re not controlled substances.

Practical Tips for Successful Telehealth ADHD Treatment

Before Your Appointment

Gather relevant information:

• List current medications and supplements
• Note previous ADHD treatments and their effects
• Prepare examples of how symptoms impact your daily life
• Collect any relevant medical records or previous evaluations
• Have insurance information ready

Choose an appropriate location:

• Private, quiet space with reliable internet
• Good lighting so the provider can see you clearly
• Minimal distractions (the provider is assessing attention!)
• Comfortable setting where you can speak openly

Prepare questions:

• What treatment options are available for my situation?
• What are the pros and cons of stimulant vs. non-stimulant medications?
• How long until I notice improvement?
• What side effects should I watch for?
• How often will we follow up?
• What should I do if I have concerns between appointments?

During Your Evaluation

Be thorough and honest:

• Provide complete symptom history, even if embarrassing
• Disclose all substance use (your provider needs this for safety)
• Mention all medical and mental health conditions
• Share concerns about specific medications
• Ask for clarification when something isn’t clear

Don’t minimize or exaggerate:

• Providers are trained to recognize both
• Accurate information leads to appropriate treatment
• Your goal is proper care, not a specific medication

After Starting Treatment

Track your response:

• Keep a symptom journal noting what improves and what doesn’t
• Record any side effects and their severity
• Note how the medication affects different aspects of life (work, relationships, daily tasks)
• Share this information at follow-up appointments

Follow your treatment plan:

• Take medication as prescribed (especially important for Strattera—it must be taken daily)
• Don’t adjust doses on your own
• Attend all follow-up appointments
• Contact your provider if you have significant concerns between visits

Consider comprehensive treatment:

• Medication is most effective combined with other strategies
• Discuss therapy or coaching options
• Implement organizational and time-management tools
• Address lifestyle factors (sleep, exercise, stress management)

Maintaining Long-Term Care

Stay proactive about refills:

• Set reminders for when to request refills
• Account for mail-order delays if applicable
• Don’t wait until you’re completely out
• For non-stimulants, you can often get 90-day supplies, reducing refill frequency

Communicate changes:

• New medical conditions
• New medications from other providers
• Changes in symptoms or medication effectiveness
• Life changes affecting ADHD management (job change, pregnancy, etc.)

Know your backup plan:

• What happens if your telehealth platform changes policies?
• Does your provider have relationships with local practices for in-person care if needed?
• Can you establish concurrent care with a local provider for continuity?

What’s Next: The Future of Telehealth ADHD Treatment

Anticipated Regulatory Changes

DEA Rules (2026 and Beyond)The current COVID-era flexibilities for controlled substance prescribing expire December 31, 2025. Several scenarios are possible:

1. Another extension (most likely in the short term)—the DEA has signaled a fourth extension is under review
2. New permanent special registration framework—the DEA proposed a ‘Special Registration’ system allowing telehealth prescribing with additional safeguards
3. Hybrid requirements—some proposals suggest requiring an in-person visit within 30 days of starting controlled medication

Important: None of these scenarios affect non-stimulant medications like Strattera. Federal restrictions only apply to controlled substances, so your access to non-stimulant ADHD treatment via telehealth should remain unaffected regardless of DEA rule changes.

State-Level Trends

Expanding access:

• More states moving toward full NP practice authority
• Permanent telehealth parity laws being adopted
• Interstate licensure compacts under consideration

Enhancing oversight:

• Mandatory PDMP checks becoming universal for controlled substances
• E-prescribing requirements expanding
• Quality standards for telehealth emerging

The trend is toward maintaining access while strengthening safeguards—good news for patients seeking legitimate care.

Technology Improvements

Telehealth platforms continue evolving:

• Better integration with electronic health records
• Enhanced diagnostic tools (symptom tracking apps, objective measures)
• Improved care coordination with other providers
• More sophisticated matching algorithms connecting patients with appropriate specialists

Platforms like Klarity Health are at the forefront of these innovations, using technology to enhance—not replace—the therapeutic relationship.

How Klarity Health Makes ADHD Treatment Accessible

Klarity Health specializes in connecting patients with licensed psychiatric providers for conditions like ADHD, offering several advantages:

Transparent, Affordable Pricing

Whether you’re using insurance or paying cash, Klarity provides upfront pricing with no hidden fees. You’ll know exactly what your appointments cost before booking, and the platform accepts both insurance and self-pay options—putting you in control of how you access care.

Provider Availability That Works for Your Schedule

Finding a psychiatrist or psychiatric nurse practitioner can mean months-long waits in many areas. Klarity’s network of licensed providers typically offers appointments within days, not months, and flexible scheduling including evenings and weekends accommodates busy lives—something particularly valuable for adults with ADHD who may struggle with rigid appointment scheduling.

Comprehensive Care Approach

Klarity providers don’t just prescribe medication. They:

• Conduct thorough diagnostic evaluations
• Discuss all treatment options (medication and non-medication)
• Provide ongoing medication management
• Can refer to therapy or coaching resources
• Coordinate with your other healthcare providers when appropriate

State-Appropriate Licensing

Klarity ensures you’re matched with a provider licensed in your state who understands local regulations. You don’t need to worry about navigating complex multi-state licensing laws—Klarity handles compliance so you can focus on your treatment.

Quality Clinical Standards

All Klarity providers follow evidence-based treatment protocols aligned with professional guidelines. The platform implements safety measures including:

• Standardized diagnostic assessments
• Regular outcome monitoring
• Appropriate prescribing safeguards
• Quality oversight

This is particularly important in ADHD treatment, where regulatory scrutiny demands rigorous clinical practices.

Take the Next Step Toward ADHD Treatment

If ADHD symptoms are impacting your work, relationships, or daily functioning, effective treatment is more accessible than ever. Non-stimulant medications like Strattera offer a legitimate treatment pathway available via telehealth without the regulatory complexity of controlled substances.

Key takeaways:

• Non-stimulant ADHD medications can be prescribed via telehealth in all 50 states
• Federal controlled substance rules don’t restrict Strattera prescribing
• Most states allow telehealth ADHD evaluation and treatment without in-person requirements
• Legitimate providers conduct comprehensive assessments similar to in-person care
• Both physicians and nurse practitioners can prescribe ADHD medications via telehealth (depending on state)
• Insurance typically covers telehealth ADHD treatment, and affordable cash-pay options exist

Whether you’re exploring ADHD treatment for the first time or looking for a more convenient way to maintain existing care, telehealth offers a valuable option. By choosing reputable providers who follow clinical best practices—like those available through Klarity Health—you can access quality ADHD care that fits your life.

Don’t let ADHD symptoms continue limiting your potential. With proper diagnosis and treatment, most people with ADHD experience significant improvement in focus, organization, time management, and overall quality of life.

Ready to take the first step? Klarity Health can connect you with a licensed provider in your state for a comprehensive ADHD evaluation. With transparent pricing, flexible scheduling, and comprehensive care, getting the ADHD treatment you need has never been more straightforward.

References and Sources

1. Fierce Healthcare. (2024, November). ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth.’ Retrieved from www.fiercehealthcare.com

2. McDermott Will & Emery LLP. (2025). ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ Retrieved from www.mwe.com

3. Sheppard Mullin Richter & Hampton LLP. (2025, August 15). ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review. Retrieved from www.sheppardhealthlaw.com

4. RxAgent. (2025, October). ‘The Telehealth Compliance Trap: Are You Breaking the Law?’ Retrieved from www.rxagent.co

5. Medical News Today. (2025, January 14). ‘Is Strattera a controlled substance?’ Retrieved from www.medicalnewstoday.com

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment